DUBLIN–(BUSINESS WIRE)–The “Rectal Cancer – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This pipeline guide, Rectal Cancer – Pipeline Review, H1 2020 provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 7, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered
- Introduction
- Rectal Cancer – Overview
- Rectal Cancer – Therapeutics Development
- Rectal Cancer – Therapeutics Assessment
- Rectal Cancer – Companies Involved in Therapeutics Development
- Rectal Cancer – Drug Profiles
- Rectal Cancer – Dormant Projects
- Rectal Cancer – Discontinued Products
- Rectal Cancer – Product Development Milestones
Companies Mentioned
- AbbVie Inc
- AD Pharmaceuticals Co Ltd
- Advaxis Inc
- Apexigen Inc
- AptaBio Therapeutics Inc
- AstraZeneca Plc
- Biotts SA
- CytomX Therapeutics Inc
- Diverse Biotech Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ellipses Pharma Ltd
- GlaxoSmithKline Plc
- Incyte Corp
- Konruns Pharmaceutical Co Ltd
- Luye Pharma Group Ltd
- Merck KGaA
- Millennium Pharmaceuticals Inc
- Oncologie Inc
- Shanghai Haihe Biopharma Co Ltd
- Stcube Inc
- Taiho Pharmaceutical Co Ltd
- Teon Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1ju8nf
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900